The paper studies the dynamics of firm growth and the firm size distribution in the pharmaceutical industry from 1950 to 2003. Growth dynamics are studied in the context of how the size composition of firms changes, how innovation patterns (patents) change, and how location leads to growth differentials among US firms. It is found that the growth advantage of small pharmaceutical firms increases after the 1980s as small firms become more active in patenting and their patenting activities become more 'persistent'. Location is found to affect growth differences only for the most innovative firms (i.e. for non innovative firms, location does not matter). For this group of firms, California firms which are much smaller in size, yet more active ...
Firms across sectors and regions are highly skewed in their ability to engage with innovation and ev...
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutic...
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutic...
The paper studies the dynamics of firm growth and the firm size distribution in the pharmaceutical i...
The paper studies the dynamics of firm growth and the firm size distribution in the pharmaceutical i...
The evolution of firm growth dynamics in the US pharmaceutical industry, Regional Studies. This pape...
If market ‘selection ’ works, and if innovation leads to greater efficiency (higher quality and/or l...
The paper contributes to an emerging literature that critically questions the degree to which R&...
The paper contributes to an emerging literature that critically questions the degree to which R&D, a...
If market ‘selection ’ works, and if innovation leads to greater efficiency (higher quality and/or l...
In this paper we present a description of growth and diversification patterns of the top firms i...
The field of modern biotechnology is thought to have largely begun in 1980, when the United States S...
The work studies the processes of growth of the world top 150 pharmaceutical firms, on the grounds o...
This work studies the processes of growth of the worlds top 150 pharmaceutical firms, on the grounds...
Firms across sectors and regions are highly skewed in their ability to engage with innovation and ev...
Firms across sectors and regions are highly skewed in their ability to engage with innovation and ev...
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutic...
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutic...
The paper studies the dynamics of firm growth and the firm size distribution in the pharmaceutical i...
The paper studies the dynamics of firm growth and the firm size distribution in the pharmaceutical i...
The evolution of firm growth dynamics in the US pharmaceutical industry, Regional Studies. This pape...
If market ‘selection ’ works, and if innovation leads to greater efficiency (higher quality and/or l...
The paper contributes to an emerging literature that critically questions the degree to which R&...
The paper contributes to an emerging literature that critically questions the degree to which R&D, a...
If market ‘selection ’ works, and if innovation leads to greater efficiency (higher quality and/or l...
In this paper we present a description of growth and diversification patterns of the top firms i...
The field of modern biotechnology is thought to have largely begun in 1980, when the United States S...
The work studies the processes of growth of the world top 150 pharmaceutical firms, on the grounds o...
This work studies the processes of growth of the worlds top 150 pharmaceutical firms, on the grounds...
Firms across sectors and regions are highly skewed in their ability to engage with innovation and ev...
Firms across sectors and regions are highly skewed in their ability to engage with innovation and ev...
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutic...
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutic...